OTCPK:BMCS

Stock Analysis Report

Executive Summary

BioTech Medics, Inc. operates as a medical-based holding company.


Snowflake Analysis

Mediocre balance sheet with weak fundamentals.

Share Price & News

How has BioTech Medics's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: BMCS's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

-2.4%

BMCS

11.6%

US Healthcare

9.4%

US Market


1 Year Return

53.8%

BMCS

7.2%

US Healthcare

-6.8%

US Market

Return vs Industry: BMCS underperformed the US Healthcare industry which returned 4.9% over the past year.

Return vs Market: BMCS exceeded the US Market which returned -8.1% over the past year.


Shareholder returns

BMCSIndustryMarket
7 Day-2.4%11.6%9.4%
30 Day29.0%-4.2%-3.9%
90 Day-9.1%-11.5%-16.5%
1 Year53.8%53.8%8.6%7.2%-4.8%-6.8%
3 Year566.7%566.7%29.7%23.9%23.4%15.2%
5 Year166.7%166.7%34.8%25.6%41.3%25.7%

Price Volatility Vs. Market

How volatile is BioTech Medics's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is BioTech Medics undervalued compared to its fair value and its price relative to the market?


In this section, we usually try to help investors determine whether BioTech Medics is trading at an attractive price based on the cash flow it is expected to produce in the future. But as BioTech Medics has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis.


Next Steps

  • Take a look at our analysis of BMCS’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  • When valuing a company like this, investors focus more on how they perceive the size of the opportunity, the company's ability to deliver and scale, and the strength of the team. While we are not analysing this type of data at the moment, if you don’t know where to start, we recommend reading through BioTech Medics regulatory filings here.
  • Explore potentially undervalued companies in the Healthcare industry.

Future Growth

How is BioTech Medics forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

13.4%

Forecasted Healthcare industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as BioTech Medics has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

  • Take a look at our analysis of BMCS’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  • While we do not consider unaudited financials to be a reliable enough to include in our analysis, you can access them on the OTC Markets Website. If you are looking for more of a qualitative research into the company, you can access BioTech Medics's filings and announcements here.
  • Explore growth companies in the Healthcare industry.

Past Performance

How has BioTech Medics performed over the past 5 years?

13.9%

Historical Healthcare annual earnings growth


In this section we usually display a company’s past earnings and revenues to help investors visualise the trend through time. We also gauge the company’s performance by benchmarking its returns and growth to its industry peers and the wider market. However, BioTech Medics has not provided sufficient past data to assess its track record.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have historical data.


Next Steps

Financial Health

How is BioTech Medics's financial position?


In this section we usually analyse BioTech Medics's finance health to determine how well-positioned it is against times of financial distress, in particular, its ability to manage its cash and debt levels. BioTech Medics has not provided adequate balance sheet data, its financial health cannot be properly assessed as it.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have financial information.


Next Steps

  • Take a look at our analysis of BMCS’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  • Investors tend to look at the financial health of a company this size in order to assess the sustainability of its current operations. While we do not consider unaudited financials to be a reliable enough to include in our analysis, you can access them on the OTC Markets Website.
  • Financial health is measured at one point in time, so the latest financial report is the best representation of the company’s current financial status. Check when BioTech Medics's financial data was last updated here.
  • Explore more healthy companies in the Healthcare industry.

Dividend

What is BioTech Medics's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate BMCS's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate BMCS's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if BMCS's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if BMCS's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of BMCS's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?


CEO

Keith Houser (70yo)

15.33s

Tenure

Mr. Keith A. Houser has been the Chairman and Chief Executive Officer of BioTech Medics, Inc. since December 7, 2004 and serves as its Interim President. Mr. Houser has over 32 years of both private and pu ...


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Insufficient data to determine if shareholders have been diluted in the past year.


Top Shareholders

Company Information

BioTech Medics, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: BioTech Medics, Inc.
  • Ticker: BMCS
  • Exchange: OTCPK
  • Founded: 1997
  • Industry: Health Care Facilities
  • Sector: Healthcare
  • Market Cap: US$689.424k
  • Shares outstanding: 172.36m
  • Website: https://null

Location

  • BioTech Medics, Inc.
  • PO Box 93476
  • Southlake
  • Texas
  • 76092-0114
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
BMCSOTCPK (Pink Sheets LLC)YesCommon StockUSUSDDec 2004

Biography

BioTech Medics, Inc. operates as a medical-based holding company. The company operates medical therapeutic laser centers that treat various pain ailments affecting the muscles, nerves, and bones, as well as arthritis. It also offers SHBAN, an antiseptic hand and body sanitizer. In addition, the company develops and sells nutraceutical products, such as BioBody Balance, a liquid vitamin concentrate; and BioBody Energy Spray, a caffeine and alcohol free natural vitamin energy spray. It offers its nutraceutical products through gross retail sales. The company was incorporated in 1997 and is based in Southlake, Texas with laser pain centers in Texas, California, New Mexico, and Florida. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/04/10 00:40
End of Day Share Price2020/04/09 00:00
Earnings2011/12/31
Annual Earnings2011/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.